Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Antifungal Drugs Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023


 

Available formats:    

StumbleUponEmail

Global Antifungal Drugs Market

 

Antifungal drugs are used in the treatment of various fungal infections, by killing the fungal cell by cell breaking and leak out the contents of cell and leads to the cell death. They also act by preventing the cell growth with minimal toxic adverse effects to the body. Fungal infections occur due to unhygienic, unclean, and dampness in the environment. Fungal infections mainly caused by the microorganisms entering into the epithelial tissue. Fungi utilizes the keratin and cause infection of the hair, skin, and nail Anti- fungal drugs enables to treat fungal infections like athlete’s foot, ringworm,  vaginal thrush, and nail infection. Systemic fungal infections are caused due to inhalation or indigestion of fungal spores and cause fungal pneumonia.

Anti fungal Drugs Market, Global Anti fungal Drugs Market, Anti fungal Market, Global Anti fungal Market, Anti fungal Drugs

Antifungal Drugs Market: 2018-2024

The antifungal drugs market is anticipated to increase at a significant CAGR over the forecast period due to rise in global population, and unhygienic environment. Burgeoning prevalence of infectious diseases, hospital acquired infections (nosocomial infections) coupled with rising awareness about the myriad fungal infections, and rising awareness of over-the-counter (OTC) antifungal drugs are the key factors expected to fuel the growth of the antifungal drugs market. In addition, rise in the R&D expenditure, increased funding from private and public  sector for dermal infections, higher prevalence of chronic conditions, including HIV and cancer, rising of immunocompromised population, and increase in awareness by organizing  patient education program are boosted the growth of antifungal drugs market over forecast period. However, the alternative therapies for fungal infections, patent expiries of branded drugs and availability of counterfeit drugs, stringent government policies, and adverse drug reactions of antifungal drugs are the major restraints for the growth of antifungal drugs over forecasting period.

 

The global antifungal drugs market is segmented on the basis of drug class, route of administration, therapeutic indication, and distribution channel

 

Based on the drug class, the market is segmented into the following:

  • Azoles
  • Polyenes
  • Echinocandins
  • Allylamines
  • Others

Based on the route of administration, the market is segmented into the following:

  • Oral
  • Parenteral
  • Topical

 

Based on therapeutic indications, the market is segmented into the following:

  • Aspergillosis
  • Candidiasis
  • Dermatophytosis
  • Others

 

Based on distribution channel, the market is segmented into the following:

  • Retail pharmacies
  • Hospital pharmacies
  • Drug stores
  • Online pharmacies

 

The global antifungal drugs market is in blooming stage, several local and international players are actively involved in the development of antifungal drugs. The collaboration of government organizations for the increase in the awareness about fungal infections is expected to unlock the potential of antifungal drugs market. For instance, In November 2013, the CDC entered into a collaborative agreement with the National Health Ministry to enhance the treatment rates of communicable diseases in emerging countries, such as Brazil and India. Major acquisitions and collaborations among companies to commercialize antifungal drugs, mergers, launching of new products, and product approvals from various drug regulatory bodies such as U.S. FDA and EMEA enable increase the global antifungal drugs market growth. For instance, in October 2009, Mylan inks licensing deal with Pfizer to start selling a U.S. generic version of Pfizer’s Vfend antifungal drug. The increase in the prevalence of fungal infections also boosts the antifungal drugs market growth. According to Centres for Disease Control and Prevention (CDC), around one million people get infected worldwide by cryptococcal meningitis, which is a brain infection caused by fungus Cryptococcus and it subsequently leads to 625,000 deaths.

 

Geographically, antifungal drugs market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Middle East and Africa, and Latin America. North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for  development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.) Europe holds a major market share in anti-fungal drugs market attributed to increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals. Asia Pacific accounts for a significant growth owing to burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about the personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in Asia-Pacific region.

 

Some of the players in antifungal drugs market are Pfizer, Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), GlaxoSmithKline plc. (U.K.), Mylan N.V. (U.S.), Tecan Group (Switzerland), and AureoGen Biosciences Inc. (U.S.), to name a few.

 

  • In February 2016, AureoGen Biosciences Inc. announced a licensing agreement with Merck, known as MSD for the development of medicines for infectious disease, including systemic fungal infections

 

  • In December 2016, The U.S. FDA has approved Eucrisa (Crisaborole) ointment manufactured by Pfizer to treat eczema

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • Pfizer, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (U.S.)
  • Enzon Pharmaceuticals, Inc. (U.S.)
  • Bayer AG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • GlaxoSmithKline plc. (U.K.)
  • Mylan N.V. (U.S.)
  • Tecan Group (Switzerland)
  • AureoGen Biosciences Inc. (U.S.)

1. Executive Summary

 

2. Global Anti fungal Drugs Market Introduction

 

2.1. Global Anti fungal Drugs Market – Taxonomy

2.2. Global Anti fungal Drugs Market –Definitions

2.2.1. Drug Class

2.2.2. Route of Administration

2.2.3. Therapeutic Indications

2.2.4. Distribution Channel

 

3. Global Anti fungal Drugs Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Anti fungal Drugs Market Dynamic Factors – Impact Analysis

3.6. Global Anti fungal Drugs Market – Competition Landscape

3.7. Epidemiology

 

4. Global Anti fungal Drugs Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market OpportunityAnalysis

 

5. Global Anti fungal Drugs Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

5.1. Azoles

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Polyenes

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Echinocandins

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Allylamines

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Others

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

 

6. Global Anti fungal Drugs Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2017 – 2024

 

6.1. Oral

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Topical

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

 

7. Global Anti fungal Drugs Market Forecast, By Therapeutic Indications, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. Aspergillosis

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Candidiasis

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Dermatophytosis

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Others

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

 

8. Global Anti fungal Drugs Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

8.1. Retail pharmacies

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Hospital pharmacies

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Drug stores

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Online pharmacies

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

Market Opportunity Analysis

 

9. Global Anti fungal Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

9.1. North America

9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

9.2. Europe

9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

9.4. Latin America

9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

 

10. North America Anti fungal Drugs MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Drug ClassAnalysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Azoles

10.1.2. Polyenes

10.1.3. Echinocandins

10.1.4. Allylamines

10.1.5. Others

10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Oral

10.2.2. Parenteral

10.2.3. Topical

10.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Aspergillosis

10.3.2. Candidiasis

10.3.3. Dermatophytosis

10.3.4. Others

10.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Retail pharmacies

10.4.2. Hospital pharmacies

10.4.3. Drug stores

10.4.4. Online pharmacies

10.5. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.5.1. U.S.

10.5.2. Canada

10.6. North America Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

10.7. North America Anti fungal Drugs Market Dynamics – Trends

 

11. Europe Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Azoles

11.1.2. Polyenes

11.1.3. Echinocandins

11.1.4. Allylamines

11.1.5. Others

11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

11.2.3. Topical

11.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Aspergillosis

11.3.2. Candidiasis

11.3.3. Dermatophytosis

11.3.4. Others

11.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.4.1. Retail pharmacies

11.4.2. Hospital pharmacies

11.4.3. Drug stores

11.4.4. Online pharmacies

11.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.5.1. Germany

11.5.2. UK

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Russia

11.5.7. Poland

11.5.8. Rest of Europe

11.6. Europe Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

11.7. Europe Anti fungal Drugs Market Dynamics – Trends

 

12. Asia-Pacific Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Azoles

12.1.2. Polyenes

12.1.3. Echinocandins

12.1.4. Allylamines

12.1.5. Others

12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

12.2.3. Topical

12.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Aspergillosis

12.3.2. Candidiasis

12.3.3. Dermatophytosis

12.3.4. Others

12.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Retail pharmacies

12.4.2. Hospital pharmacies

12.4.3. Drug stores

12.4.4. Online pharmacies

12.5. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. ASEAN

12.5.5. Australia & New Zealand

12.5.6. Rest of Asia-Pacific

12.6. Asia-Pacific Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

12.7. Asia-Pacific Anti fungal Drugs Market Dynamics – Trends

 

13. Latin America Anti fungal Drugs Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Azoles

13.1.2. Polyenes

13.1.3. Echinocandins

13.1.4. Allylamines

13.1.5. Others

13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

13.2.3. Topical

13.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Aspergillosis

13.3.2. Candidiasis

13.3.3. Dermatophytosis

13.3.4. Others

13.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Retail pharmacies

13.4.2. Hospital pharmacies

13.4.3. Drug stores

13.4.4. Online pharmacies

13.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Argentina

13.5.4. Venezuela

13.5.5. Rest of Latin America

13.6. Latin America Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

13.7. Latin America Anti fungal Drugs Market Dynamics – Trends

 

14. Middle East and Africa Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

14.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

14.1.1. Azoles

14.1.2. Polyenes

14.1.3. Echinocandins

14.1.4. Allylamines

14.1.5. Others

14.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.2.1. Oral

14.2.2. Parenteral

14.2.3. Topical

14.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.3.1. Aspergillosis

14.3.2. Candidiasis

14.3.3. Dermatophytosis

14.3.4. Others

14.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.4.1. Retail pharmacies

14.4.2. Hospital pharmacies

14.4.3. Drug stores

14.4.4. Online pharmacies

14.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

14.5.1. Gulf Cooperation Council (GCC) Countries

14.5.2. Israel

14.5.3. South Africa

14.5.4. Rest of MEA

14.6. MEA Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

14.7. MEA Anti fungal Drugs Market Dynamics – Trends

 

15. Competition Landscape

 

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. Pfizer, Inc. (U.S.)

15.2.2. Novartis AG (Switzerland)

15.2.3. Sanofi (France)

15.2.4. Merck & Co., Inc. (U.S.)

15.2.5. Enzon Pharmaceuticals, Inc. (U.S.)

15.2.6. Bayer AG (Germany)

15.2.7. Astellas Pharma, Inc. (Japan)

15.2.8. GlaxoSmithKline plc. (U.K.)

15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland)

15.2.10. AureoGen Biosciences Inc. (U.S.)

 

16. Research Methodology

17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR

CALL US ON : 123456789

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553